Literature DB >> 18563327

Application of proton magnetic resonance spectroscopy and computerized tomography in the diagnosis and treatment of nonalcoholic fatty liver disease.

Nan Wang1, Hui Dong, Shichao Wei, Fuer Lu.   

Abstract

In order to investigate the application of proton magnetic resonance spectroscopy ((1)H-MRS) and computerized tomography (CT) in the quantitative diagnosis of nonalcoholic fatty liver disease (NAFLD) and evaluation of therapeutic effects, 22 patients with NAFLD were selected according to the Chinese Medical Association's (CMA) standard of the NAFLD in comparison with 20 healthy volunteers (as control group). Blood samples for biochemistry were collected. The severity of hepatosteatosis was evaluated by (1)H-MRS scan and CT scan of liver. The intrahepatic content of lipid (IHCL) and CT value ratio of liver to spleen were calculated. The patients in NAFLD group were treated with Ganzhixiao Capsule for 8 weeks. The changes in IHCL and CT value ratio of liver to spleen were observed before and after treatment. In NAFLD group serum ALT, TG, IHCL calculated by (1)HMRS were increased and CT value ratio of liver to spleen decreased significantly as compared with control group. After treatment for 8 weeks serum ALT, TG, IHCL were decreased significantly, while CT value ratio of liver to spleen increased significantly in NAFLD group. It was suggested that IHCL could be measured precisely by (1)HMRS. NAFLD was treated effectively by Ganzhixiao capsule.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563327     DOI: 10.1007/s11596-008-0315-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  5 in total

1.  Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw.

Authors:  Hui Dong; Fu-Er Lu; Zhi-Qiang Gao; Li-Jun Xu; Kai-Fu Wang; Xin Zou
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

2.  Effect of voxel position on single-voxel MR spectroscopy findings.

Authors:  P E Ricci; A Pitt; P J Keller; S W Coons; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

3.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Authors:  Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

4.  Fatty infiltration of the liver: demonstration by proton spectroscopic imaging. Preliminary observations.

Authors:  J K Lee; W T Dixon; D Ling; R G Levitt; W A Murphy
Journal:  Radiology       Date:  1984-10       Impact factor: 11.105

5.  Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.

Authors:  S Nair; A M Diehl; M Wiseman; G H Farr; R P Perrillo
Journal:  Aliment Pharmacol Ther       Date:  2004-07-01       Impact factor: 8.171

  5 in total
  5 in total

Review 1.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

Review 2.  Herbal medicines and nonalcoholic fatty liver disease.

Authors:  Hong Yao; Yu-Jie Qiao; Ya-Li Zhao; Xu-Feng Tao; Li-Na Xu; Lian-Hong Yin; Yan Qi; Jin-Yong Peng
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

3.  Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities.

Authors:  Hui Dong; Fu'er Lu; Nan Wang; Xin Zou; Jingjing Rao
Journal:  Front Med       Date:  2011-10-02       Impact factor: 4.592

4.  Role of serum hyaluronic acid in predicting necroinflammatory activity of the nonalcoholic fatty liver disease.

Authors:  Hakan Guveli; Oya Ovunc Kurdas
Journal:  Hepatol Forum       Date:  2022-04-26

5.  Jiao tai wan attenuates hepatic lipid accumulation in type 2 diabetes mellitus.

Authors:  Zhaoyi Huang; Xiaohu Xu; Fuer Lu; Nan Wang; Guang Chen; Yan Zhao; Xin Zou; Kaifu Wang; Hui Dong; Lijun Xu
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-10       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.